Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 96 (6) , 1303-1307
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of War
- Doris Duke Charitable Foundation
- National Institutes of Health
- Nephcure
This publication has 18 references indexed in Scilit:
- ApoL1 Overexpression Drives Variant-Independent CytotoxicityJournal of the American Society of Nephrology, 2017
- Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy DepletionJournal of the American Society of Nephrology, 2017
- Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in miceNature Medicine, 2017
- APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell DeathJournal of the American Society of Nephrology, 2016
- APOL1–Mediated Cell Injury Involves Disruption of Conserved Trafficking ProcessesJournal of the American Society of Nephrology, 2016
- APOL1 Renal-Risk Variants Induce Mitochondrial DysfunctionJournal of the American Society of Nephrology, 2016
- Apolipoprotein L1 and Kidney Disease in African AmericansTrends in Endocrinology & Metabolism, 2016
- Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieuExperimental and Molecular Pathology, 2015
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010
- Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHuman Genetics, 2010